Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Acq. announced
Appointed director
Quarterly results
CC transcript
GENZYME CORP (GENZ) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/07/2011 BW Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares
03/01/2011 BW Genzyme Completes Sale of Pharmaceuticals Business to International Chemical Investors Group
02/18/2011 BW Three-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Further Improvement Across All Endpoints
02/16/2011 BW Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year
12/13/2010 BW Genzyme to Hold Investor Event on Alemtuzumab
12/13/2010 BW Genzyme Reiterates Board's Position on Sanofi-Aventis Tender Offer
12/01/2010 BW Genzyme Completes Sale of Genetic Testing Business to LabCorp
11/24/2010 BW Genzyme Successfully Meets First Milestones of FDA Consent Decree
11/18/2010 BW Genzyme Announces Agreement to Sell Diagnostics Business to Sekisui Chemical Co.
10/21/2010 BW Genzyme Announces Webcast of Analyst and Investor Event
10/20/2010 BW Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML
10/20/2010 BW Genzyme Reports Financial Results for the Third Quarter of 2010
10/20/2010 BW Genzyme Reports Financial Results for the Third Quarter of 2010
10/14/2010 BW Genzyme's Alemtuzumab Shows Sustained Reduction in Relapses and Disability in Five-Year Review of MS Patients from Phase 2 Trial
10/07/2010 BW Genzyme Board Unanimously Rejects Sanofi-Aventis Tender Offer
09/20/2010 BW Synvisc Approved in Japan, Key Market for Viscosupplementation Products
08/30/2010 BW Genzyme Confirms Receipt of Unsolicited Proposal
08/23/2010 BW Two-Year Data from Phase 2 Trial of Genzyme's Eliglustat Tartrate for Gaucher Disease To Be Published in the Journal Blood
07/21/2010 BW Genzyme Reports Financial Results for the Second Quarter of 2010
06/18/2010 BW Genzyme Announces Accelerated Share Repurchase
06/16/2010 BW Shareholders Re-Elect All Members of Genzyme's Board of Directors
06/15/2010 BW Genzyme Prices Private Senior Notes Offerings
06/14/2010 BW Genzyme's Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA
06/09/2010 BW Genzyme and Carl Icahn Reach Agreement
06/07/2010 BW Dennis Fenton Nominated for Election to Genzyme's Board of Directors
05/06/2010 BW Genzyme Announces $2 Billion Stock Repurchase
04/21/2010 BW Genzyme Reports Financial Results for the First Quarter of 2010
04/15/2010 BW Genzyme Study of Myozyme Treatment for Pompe Disease Published in New England Journal of Medicine
04/15/2010 BW Ralph Whitworth Elected to Genzyme's Board of Directors
04/08/2010 BW Genzyme Sets June 16 Date for Annual Meeting of Shareholders
03/31/2010 BW Genzyme to Host Investor Event on Its Manufacturing Operations
03/30/2010 BW Genzyme Creates Chief Operating Officer Position
03/24/2010 BW Genzyme Announces FDA Enforcement Action Regarding Allston Plant
03/15/2010 BW Mipomersen Phase 3 Study in HoFH Patients Featured in The Lancet
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy